Body Weight Loss by Very-Low-Calorie Diet Program Improves Small Artery Reactive Hyperemia in Severely Obese Patients

2012 ◽  
Vol 23 (1) ◽  
pp. 17-23 ◽  
Author(s):  
J. Merino ◽  
I. Megias-Rangil ◽  
R. Ferré ◽  
N. Plana ◽  
J. Girona ◽  
...  
Keyword(s):  
Weight Loss ◽  
Body Weight ◽  
Reactive Hyperemia ◽  
Body Weight Loss ◽  
Obese Patients ◽  
Small Artery ◽  
Very Low Calorie Diet ◽  
Low Calorie Diet ◽  
Calorie Diet ◽  
Severely Obese

scholarly journals Effects of a 3-Week Hospital-Controlled Very-Low-Calorie Diet in Severely Obese Patients

Nutrients ◽  
2021 ◽  
Vol 13 (12) ◽  
pp. 4468
Author(s):  
Ivan Ožvald ◽  
Dragan Božičević ◽  
Lidija Duh ◽  
Ivana Vinković Vrček ◽  
Ivan Pavičić ◽  
...  
Keyword(s):  
Dna Damage ◽  
Weight Loss ◽  
Health Improvement ◽  
Healthy Population ◽  
Obese Patients ◽  
Very Low Calorie Diet ◽  
Low Calorie ◽  
Low Calorie Diet ◽  
Calorie Diet ◽  
Severely Obese

Although a very-low-calorie diet (VLCD) is considered safe and has demonstrated benefits among other types of diets, data are scarce concerning its effects on improving health and weight loss in severely obese patients. As part of the personalized weight loss program developed at the Duga Resa Special Hospital for Extended Treatment, Croatia, we evaluated anthropometric, biochemical, and permanent DNA damage parameters (assessed with the cytochalasin B-blocked micronucleus cytome assay—CBMN) in severely obese patients (BMI ≥ 35 kg m−2) after 3-weeks on a 567 kcal, hospital-controlled VLCD. This is the first study on the permanent genomic (in)stability in such VLCD patients. VLCDs caused significant decreases in weight (loss), parameters of the lipid profile, urea, insulin resistance, and reduced glutathione (GSH). Genomic instability parameters were lowered by half, reaching reference values usually found in the healthy population. A correlation was found between GSH decrease and reduced DNA damage. VLCDs revealed susceptible individuals with remaining higher DNA damage for further monitoring. In a highly heterogeneous group (class II and III in obesity, differences in weight, BMI, and other categories) consisting of 26 obese patients, the approach demonstrated its usefulness and benefits in health improvement, enabling an individual approach to further monitoring, diagnosis, treatment, and risk assessment based on changing anthropometric/biochemical VLCD parameters, and CBMN results.

scholarly journals Effect of Mazindol on Body Weight and Insulin Sensitivity in Severely Obese Patients after a Very-Low-Calorie Diet Therapy.

1996 ◽  
Vol 43 (6) ◽  
pp. 671-677 ◽  
Author(s):  
TETSUO NISHIKAWA ◽  
TAKASHI IIZUKA ◽  
MASAO OMURA ◽  
NOBUHIKO KURAMOTO ◽  
TAKASHI MIKI ◽  
...  
Keyword(s):  
Body Weight ◽  
Insulin Sensitivity ◽  
Diet Therapy ◽  
Obese Patients ◽  
Very Low Calorie Diet ◽  
Low Calorie ◽  
Low Calorie Diet ◽  
Calorie Diet ◽  
Severely Obese

scholarly journals Protocol for a randomised controlled trial of the combined effects of the GLP-1 receptor agonist liraglutide and exercise on maintenance of weight loss and health after a very low-calorie diet

BMJ Open ◽  
2019 ◽  
Vol 9 (11) ◽  
pp. e031431
Author(s):  
Simon Birk Kjær Jensen ◽  
Julie Rehné Lundgren ◽  
Charlotte Janus ◽  
Christian Rimer Juhl ◽  
Lisa Møller Olsen ◽  
...  
Keyword(s):  
Weight Loss ◽  
Body Weight ◽  
Receptor Agonist ◽  
Controlled Trial ◽  
Good Clinical Practice ◽  
Study Groups ◽  
Very Low Calorie Diet ◽  
Low Calorie ◽  
Low Calorie Diet ◽  
Calorie Diet

IntroductionThe success rate of weight loss maintenance is limited. Therefore, the purpose of this study is to investigate the maintenance of weight loss and immunometabolic health outcomes after diet-induced weight loss followed by 1-year treatment with a glucagon-like peptide-1 receptor agonist (liraglutide), physical exercise or the combination of both treatments as compared with placebo in individuals with obesity.Methods and analysisThis is an investigator-initiated, randomised, placebo-controlled, parallel group trial. We will enrol expectedly 200 women and men (age 18–65 years) with obesity (body mass index 32–43 kg/m2) to adhere to a very low-calorie diet (800 kcal/day) for 8 weeks in order to lose at least 5% of body weight. Subsequently, participants will be randomised in a 1:1:1:1 ratio to one of four study groups for 52 weeks: (1) placebo, (2) exercise 150 min/week+placebo, (3) liraglutide 3.0 mg/day and (4) exercise 150 min/week+liraglutide 3.0 mg/day. The primary endpoint is change in body weight from randomisation to end-of-treatment.Ethics and disseminationThe trial has been approved by the ethical committee of the Capital Region of Denmark and the Danish Medicines Agency. The trial will be conducted in agreement with the Declaration of Helsinki and monitored to follow the guidelines for good clinical practice. Results will be submitted for publication in international peer-reviewed scientific journals.Trial registration number2015-005585-32

Clinical Impact of a 6-Week Preoperative Very Low Calorie Diet on Body Weight and Liver Size in Morbidly Obese Patients

2013 ◽  
Vol 23 (10) ◽  
pp. 1624-1631 ◽  
Author(s):  
Jordán González-Pérez ◽  
Sofía Sánchez-Leenheer ◽  
Alfredo Rivas Delgado ◽  
Lizbeth González-Vargas ◽  
Mariana Díaz-Zamudio ◽  
...  
Keyword(s):  
Body Weight ◽  
Clinical Impact ◽  
Morbidly Obese ◽  
Obese Patients ◽  
Very Low Calorie Diet ◽  
Liver Size ◽  
Low Calorie ◽  
Low Calorie Diet ◽  
Calorie Diet

scholarly journals Body weight loss reverts obesity-associated hypogonadotropic hypogonadism: a systematic review and meta-analysis

2013 ◽  
Vol 168 (6) ◽  
pp. 829-843 ◽  
Author(s):  
Giovanni Corona ◽  
Giulia Rastrelli ◽  
Matteo Monami ◽  
Farid Saad ◽  
Michaela Luconi ◽  
...  
Keyword(s):  
Systematic Review ◽  
Bariatric Surgery ◽  
Weight Loss ◽  
Body Weight ◽  
Meta Analysis ◽  
Body Weight Loss ◽  
Low Calorie ◽  
Testosterone Levels ◽  
Low Calorie Diet ◽  
Calorie Diet

ObjectiveFew randomized clinical studies have evaluated the impact of diet and physical activity on testosterone levels in obese men with conflicting results. Conversely, studies on bariatric surgery in men generally have shown an increase in testosterone levels. The aim of this study is to perform a systematic review and meta-analysis of available trials on the effect of body weight loss on sex hormones levels.DesignMeta-analysis.MethodsAn extensive Medline search was performed including the following words: ‘testosterone’, ‘diet’, ‘weight loss’, ‘bariatric surgery’, and ‘males’. The search was restricted to data from January 1, 1969 up to August 31, 2012.ResultsOut of 266 retrieved articles, 24 were included in the study. Of the latter, 22 evaluated the effect of diet or bariatric surgery, whereas two compared diet and bariatric surgery. Overall, both a low-calorie diet and bariatric surgery are associated with a significant (P<0.0001) increase in plasma sex hormone-binding globulin-bound and -unbound testosterone levels (total testosterone (TT)), with bariatric surgery being more effective in comparison with the low-calorie diet (TT increase: 8.73 (6.51–10.95) vs 2.87 (1.68–4.07) for bariatric surgery and the low-calorie diet, respectively; both P<0.0001 vs baseline). Androgen rise is greater in those patients who lose more weight as well as in younger, non-diabetic subjects with a greater degree of obesity. Body weight loss is also associated with a decrease in estradiol and an increase in gonadotropins levels. Multiple regression analysis shows that the degree of body weight loss is the best determinant of TT rise (B=2.50±0.98, P=0.029).ConclusionsThese data show that weight loss is associated with an increase in both bound and unbound testosterone levels. The normalization of sex hormones induced by body weight loss is a possible mechanism contributing to the beneficial effects of surgery in morbid obesity.

Sign in / Sign up

Export Citation Format

Share Document